Cardiometabolic Risk Factors Impair Recompensation and Survival in Alcohol-Associated Liver Disease

Hepatology

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol

Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Pecorella F, Di Maria G, Enea M, Midiri F, Mantovani A, Targher G, Krag A, Rinella ME, Cammà C, Petta S

doi: 10.1016/S2468-1253(25)00188-8

Hepatology

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

BMC Gastroenterol

Shin WY, Kang ES, Oh YH, Sha M, Xia Q, Jeong S, Cho Y

doi: 10.1186/s12876-025-03814-1

Hepatology

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

J Gastroenterol Hepatol

Hsieh ML, Su TH, Lin YC, Chen YY, Tung CF, Huang LS, Wu CH, Peng YC, Hsieh VC

doi: 10.1111/jgh.70259

Hepatology

Longitudinal Changes in Cardiometabolic Risk Factors are Associated with Changes in Liver Stiffness in Adults with MASLD

J Hepatol

Dukewich M, Wilson LA, Dodge JL, Yuan L, Hameed B, Yates KP, Loomba R, Neuschwander-Tetri BA, Mack W, Terrault N, NASH Clinical Research Network

doi: 10.1016/j.jhep.2026.02.002

HepatitisHepatology

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Chang YP, Chen YC, Cheng PN, Fang YJ, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Lee FJ, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH, Liu CH

doi: 10.1136/gutjnl-2025-337275

HepatitisHepatology

Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease

J Hepatol

Fondevila MF, Kreimeyer H, Hsu CL, Tamargo-Azpilicueta J, Day LZ, Gritsenko M, Attah K, Cabré N, Harberts A, Tonetti FR, Yang Y, Yamazaki T, Schöler D, Eguileor A, Blasio C, Meijnikman AS, Zhang X, Garcia-Carbonell R, Hook V, Zhou E, Sun Z, Jacobs JM, Turner JR, Llorente C, AlcHepNet Investigators, Glass CK, Stärkel P, Reinheckel T, Diaz-Moreno I, Gonzalez DJ, Schnabl B

doi: 10.1016/j.jhep.2026.01.013

Further Publications

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

Am J Gastroenterol

Barritt AS 4th, Tapper EB, Newsome PN, Gazis D, Morris H, Mospan AR, Perez AD, Kim Y, Neuschwander-Tetri BA, Loomba R, Sanyal A, TARGET-NASH Investigators

doi: 10.14309/ajg.0000000000003595

Helicobacter Pylori

Effects of Helicobacter pylori Eradication on the Risk and Clinical Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Helicobacter

Li X, Tao Y, Li H, Mai L, He X, Yan J, Yang X

doi: 10.1111/hel.70092

Gastrointestinal CancerHepatology

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Lai JC, Yang B, Lee HW, Lin H, Tsochatzis EA, Petta S, Bugianesi E, Yoneda M, Zheng MH, Hagström H, Boursier J, Calleja JL, Goh GB, Chan WK, Gallego-Duràn R, Sanyal AJ, de Lédinghen V, Newsome PN, Fan JG, Castera L, Lai M, Fournier-Poizat C, Wong GL, Pennisi G, Armandi A, Nakajima A, Liu WY, Shang Y, Saint-Loup M, Llop E, Teh KKJ, Lara-Romero C, Asgharpour A, Mahgoub S, Chan MS, Canivet CM, Romero-Gómez M, Kim SU, Wong VW, Yip TC

doi: 10.1136/gutjnl-2025-334981

Related content

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study : MASLD, MetALD, and dementia risk

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

Longitudinal Changes in Cardiometabolic Risk Factors are Associated with Changes in Liver Stiffness in Adults with MASLD

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease

Cardiovascular risk assessment tools are insufficient for patients with metabolic dysfunction associated steatotic liver disease

Effects of Helicobacter pylori Eradication on the Risk and Clinical Parameters of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis

Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease